GlassScriptPhysician profile
Ting Han
NPI 1306472238
$3,221.87
in general payments reported to CMS, 2019-2025
33 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $398 · 2024: $1,453 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.85 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $379.00 | 2024-2025 | Airsupra, Farxiga, Saphnelo |
| Abbvie INC. | $293.92 | 2023-2025 | |
| Amgen INC. | $276.21 | 2023-2025 | Prolia, Tepezza, Krystexxa |
| Pfizer INC. | $209.34 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $169.52 | 2024-2025 | Voquezna |
| Ucb, INC. | $149.08 | 2023-2024 | Cimzia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.19 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $113.06 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $78.80 | 2024-2025 | |
| Averitas Pharma INC. | $70.93 | 2023-2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $66.64 | 2023-2024 | Strensiq |
| Daiichi Sankyo INC. | $65.97 | 2024 | Injectafer |
| Radius Health, INC. | $64.45 | 2023-2025 | Tymlos |
| Janssen Biotech, INC. | $57.33 | 2024 | Tremfya |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.04 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $52.48 | 2024-2025 | |
| Boston Scientific Corporation | $47.85 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Calliditas Therapeutics US INC. | $46.55 | 2023 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $43.97 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $40.85 | 2024 | Rexulti |
| Dexcom, INC. | $31.92 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $28.02 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $27.46 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.91 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.55 | 2024 | Ofev |
| Horizon Therapeutics Plc | $22.21 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $21.57 | 2024 | Lupkynis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.75 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $16.55 | 2024 | Trintellix |
| Currax Pharmaceuticals LLC | $16.07 | 2024 | Contrave |
| Kiniksa Pharmaceuticals, LTD. | $14.99 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $13.84 | 2024 | Gardasil 9, Capvaxive, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.